trial · primary record
Eflapegrastim
Solid Tumors
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2027-10 |
| Primary endpoint | Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
| Registry ID | NCT04570423 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:32.352Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04570423
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.